New Medicines in Wales: The All Wales Medicines Strategy Group (AWMSG) Appraisal Process and Outcomes

Research output: Contribution to journalArticlepeer-review

Standard Standard

New Medicines in Wales: The All Wales Medicines Strategy Group (AWMSG) Appraisal Process and Outcomes. / Varnava, Alice; Samuels, Karen ; Hughes, Dyfrig et al.
In: Pharmacoeconomics, Vol. 36, No. 5, 05.2018, p. 613-624.

Research output: Contribution to journalArticlepeer-review

HarvardHarvard

APA

CBE

MLA

VancouverVancouver

Varnava A, Samuels K, Hughes D, Routledge PA. New Medicines in Wales: The All Wales Medicines Strategy Group (AWMSG) Appraisal Process and Outcomes. Pharmacoeconomics. 2018 May;36(5):613-624. Epub 2018 Mar 8. doi: 10.1007/s40273-018-0632-7

Author

Varnava, Alice ; Samuels, Karen ; Hughes, Dyfrig et al. / New Medicines in Wales : The All Wales Medicines Strategy Group (AWMSG) Appraisal Process and Outcomes. In: Pharmacoeconomics. 2018 ; Vol. 36, No. 5. pp. 613-624.

RIS

TY - JOUR

T1 - New Medicines in Wales

T2 - The All Wales Medicines Strategy Group (AWMSG) Appraisal Process and Outcomes

AU - Varnava, Alice

AU - Samuels, Karen

AU - Hughes, Dyfrig

AU - Routledge, Philip A.

PY - 2018/5

Y1 - 2018/5

N2 - BackgroundThe All Wales Medicines Strategy Group (AWMSG) develops prescribing advice and is responsible for appraising new medicines for use in Wales. In this article, we examine the medicines appraisal process in Wales, its timeliness and its impact on medicines availability in Wales, and compare its processes and recommendations with the two other UK health technology appraisal bodies [the National Institute for Health and Care Excellence (NICE) and the Scottish Medicines Consortium (SMC)].MethodsWe reviewed the medicines appraisals conducted by AWMSG between October 2010 and September 2015. The duration of the process and the recommendations made by AWMSG were compared with those of NICE and SMC. Only publicly available data were considered in this review.ResultsAWMSG conducted 171 single technology appraisals for 137 medicines during the study period (34 were for medicines previously appraised by AWMSG but these were for new indications). Of these, 152 appraisals were supported for use in NHS Wales (33 with restrictions) and 19 were not supported. Recommendations broadly concurred with SMC and NICE for the majority of appraisals. Compared with NICE recommendations, the median time advantage gained in Wales for those medicines that received a positive AWMSG recommendation and which were subsequently superseded by NICE advice was 10.6 months (range 3.5–48.3 months; n = 17).ConclusionThis review highlights the work carried out by AWMSG over a 5-year period, and provides evidence to support the effectiveness of the appraisal process in terms of patients in Wales gaining earlier access to medicines and efficiency through reduced duplication with NICE.

AB - BackgroundThe All Wales Medicines Strategy Group (AWMSG) develops prescribing advice and is responsible for appraising new medicines for use in Wales. In this article, we examine the medicines appraisal process in Wales, its timeliness and its impact on medicines availability in Wales, and compare its processes and recommendations with the two other UK health technology appraisal bodies [the National Institute for Health and Care Excellence (NICE) and the Scottish Medicines Consortium (SMC)].MethodsWe reviewed the medicines appraisals conducted by AWMSG between October 2010 and September 2015. The duration of the process and the recommendations made by AWMSG were compared with those of NICE and SMC. Only publicly available data were considered in this review.ResultsAWMSG conducted 171 single technology appraisals for 137 medicines during the study period (34 were for medicines previously appraised by AWMSG but these were for new indications). Of these, 152 appraisals were supported for use in NHS Wales (33 with restrictions) and 19 were not supported. Recommendations broadly concurred with SMC and NICE for the majority of appraisals. Compared with NICE recommendations, the median time advantage gained in Wales for those medicines that received a positive AWMSG recommendation and which were subsequently superseded by NICE advice was 10.6 months (range 3.5–48.3 months; n = 17).ConclusionThis review highlights the work carried out by AWMSG over a 5-year period, and provides evidence to support the effectiveness of the appraisal process in terms of patients in Wales gaining earlier access to medicines and efficiency through reduced duplication with NICE.

U2 - 10.1007/s40273-018-0632-7

DO - 10.1007/s40273-018-0632-7

M3 - Article

VL - 36

SP - 613

EP - 624

JO - Pharmacoeconomics

JF - Pharmacoeconomics

SN - 1170-7690

IS - 5

ER -